Anti-fibrotic agent pirfenidone inhibits cell growth of human cancer cells

被引：0
|
作者：
Usugi, Eri [1 ]
Ishii, Kenichiro [1 ]
Kanayama, Kazuki [2 ]
Shiraishi, Taizo [3 ]
Hirokawa, Yoshifumi [1 ]
机构：
[1] Mie Univ, Grad Sch Med, Dept Oncol Pathol, Tsu, Mie, Japan
[2] Suzuka Univ Med Sci, Dept Clin Nutr, Suzuka, Mie, Japan
[3] Kuwana City Med Ctr, Kuwana, Mie, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Pancreatic cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2279
引用
收藏
页码：708 / 708
页数：1
相关论文
共 50 条
  • [1] The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
    Melanie Mediavilla-Varela
    Kingsley Boateng
    David Noyes
    Scott J. Antonia
    BMC Cancer, 16
  • [2] The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
    Mediavilla-Varela, Melanie
    Boateng, Kingsley
    Noyes, David
    Antonia, Scott J.
    BMC CANCER, 2016, 16
  • [3] Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest
    Ishii, Kenichiro
    Sasaki, Takeshi
    Iguchi, Kazuhiro
    Kato, Manabu
    Kanda, Hideki
    Hirokawa, Yoshifumi
    Arima, Kiminobu
    Watanabe, Masatoshi
    Sugimura, Yoshiki
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (01)
  • [4] Mechanisms of the Anti-Fibrotic Effects of Pirfenidone
    Dsouza, K. G.
    Logsdon, N. J.
    Chanda, D.
    Kurundkar, D.
    Thannickal, V. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection
    Dosanjh, A
    Ikonen, T
    Wan, B
    Morris, RE
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2002, 15 (05) : 433 - 437
  • [6] Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients
    Dosanjh, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (03) : 219 - 222
  • [7] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
    M. Molina-Molina
    C. Machahua-Huamani
    V. Vicens-Zygmunt
    R. Llatjós
    I. Escobar
    E. Sala-Llinas
    P. Luburich-Hernaiz
    J. Dorca
    A. Montes-Worboys
    BMC Pulmonary Medicine, 18
  • [8] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
    Molina-Molina, M.
    Machahua-Huamani, C.
    Vicens-Zygmunt, V.
    Llatjos, R.
    Escobar, I.
    Sala-Llinas, E.
    Luburich-Hernaiz, P.
    Dorca, J.
    Montes-Worboys, A.
    BMC PULMONARY MEDICINE, 2018, 18
  • [9] Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
    Andersen, Stine
    Axelsen, Julie Birkmose
    Ringgaard, Steffen
    Nyengaard, Jens Randel
    Nielsen, Signe Holm
    Genovese, Federica
    Karsdal, Morten Asser
    Hyldebrandt, Janus Adler
    Sorensen, Charlotte Brandt
    de Man, Frances S.
    Bogaard, Harm Jan
    Nielsen-Kudsk, Jens Erik
    Andersen, Asger
    PULMONARY CIRCULATION, 2019, 9 (02)
  • [10] Pirfenidone: an anti-fibrotic therapy for progressive kidney disease
    Cho, Monique E.
    Kopp, Jeffrey B.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (02) : 275 - 283
12345